Pfizer Inc (PFE)

PFE (NYSE:Drugs)
$29.38
neg -0.11
-0.37%
Today's Range: 29.36 - 29.67 | PFE Avg Daily Volume: 23,205,100
Last Update: 08/28/14 - 4:01 PM EDT
Volume: 19,547,781
YTD Performance: -3.72%
Open: $29.43
Previous Close: $29.49
52 Week Range: $27.81 - $32.96
Oustanding Shares: 6,340,863,126
Market Cap: 185,216,611,910
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 5
Moderate Buy 1 1 1 2
Hold 4 4 4 3
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.08 2.08 2.08 2.05
Latest Dividend: 0.26
Latest Dividend Yield: 3.56%
Dividend Ex-Date: 07/30/14
Price Earnings Ratio: 18.37
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
18.37 18.00 28.96
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-0.41% 5.34% 61.94%
GROWTH 12 Mo 3 Yr CAGR
Revenue -12.50 -0.24 -0.09
Net Income 51.20 0.38 0.11
EPS 64.40 2.14 0.46
Earnings for PFE:
EBITDA 22.78B
Revenue 51.58B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.55 $0.55 $2.25 $2.25
Number of Analysts 7 6 10 10
High Estimate $0.57 $0.56 $2.29 $2.38
Low Estimate $0.53 $0.52 $2.22 $2.15
Prior Year $0.58 $0.56 $2.22 $2.25
Growth Rate (Year over Year) -4.93% -2.68% 1.58% -0.31%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bullishPfizer rated new Buy at Deutsche

Aug 27, 2014 | 7:13 AM EDT

PFE was initiated with a Buy rating, Deutsche Bank said. $34 price target. Company has a strong financial position, with attractive valuation and dividend. 

By

Gary Berman

 | Aug 25, 2014 | 9:55 AM EDT

A long-term oversold signal is in place, but wait for a close above this level before you buy.

By

Gary Dvorchak

 | Aug 13, 2014 | 11:00 AM EDT

The most attractive dividends coming in the next week.

By

Jim Cramer

 | Jul 30, 2014 | 7:38 AM EDT

We have seen a huge correction, and we now need to look for signs that it is ending.

By

Doug Kass

 | Jul 29, 2014 | 7:43 AM EDT
Where it began.

bearishPfizer downgraded at BMO

Jul 28, 2014 | 7:56 AM EDT

PFE was downgraded to Market Perform, BMO Capital said. $31 price target. Company has limited growth prospects.

By

Jim Cramer

 | Jul 28, 2014 | 6:45 AM EDT

If you insist on playing it, recognize the 50/50 nature of the scenario.

By

Jim Cramer

 | Jul 17, 2014 | 7:10 AM EDT

If you're worried about these moves, it's time to cash out.

By

Dick Arms

 | Jul 8, 2014 | 7:00 AM EDT

Instead, in light of recent action, we should be extremely cautious.

By

Jim Cramer

 | Jul 7, 2014 | 11:18 AM EDT

A wave of M&A in the health sector makes sense.

If this market has taught us one thing over the past 5 years, it has been to not be dogmat...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Bef...
Market recovers a bit from early losses after European Bourses close at 11:30am EST. Upwa...
When I do an article on a stock I do my best to define the risk on the trade. Sometimes I...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.